Richard Kim, MD, Moffitt Cancer Center

Articles by Richard Kim, MD, Moffitt Cancer Center

Updates in Frontline Treatment of Metastatic Liver Cancer

ByRichard S. Finn, MD, UCLA Health,Richard Kim, MD, Moffitt Cancer Center,Riad Salem, MD, Northwestern University Feinberg School of Medicine,Amit Singal, MD, UT Southwestern Medical Center

July 24th 2020

Future Directions for mHCC

ByRichard S. Finn, MD, UCLA Health,Richard Kim, MD, Moffitt Cancer Center,Riad Salem, MD, Northwestern University Feinberg School of Medicine,Amit Singal, MD, UT Southwestern Medical Center

July 24th 2020

mHCC: Influence of PD-L1 Inhibitors on Second-Line Therapy

ByRichard S. Finn, MD, UCLA Health,Richard Kim, MD, Moffitt Cancer Center,Riad Salem, MD, Northwestern University Feinberg School of Medicine,Amit Singal, MD, UT Southwestern Medical Center

July 24th 2020

ASCO 2020 Data for Treatment of Advanced HCC

ByRichard S. Finn, MD, UCLA Health,Richard Kim, MD, Moffitt Cancer Center,Riad Salem, MD, Northwestern University Feinberg School of Medicine,Amit Singal, MD, UT Southwestern Medical Center

July 24th 2020

ASCO 2020: HIMALAYA Trial for Advanced HCC

ByRichard S. Finn, MD, UCLA Health,Richard Kim, MD, Moffitt Cancer Center,Riad Salem, MD, Northwestern University Feinberg School of Medicine,Amit Singal, MD, UT Southwestern Medical Center

July 24th 2020

Role of VEGF TKIs for Treatment of HCC

ByRichard S. Finn, MD, UCLA Health,Richard Kim, MD, Moffitt Cancer Center,Riad Salem, MD, Northwestern University Feinberg School of Medicine,Amit Singal, MD, UT Southwestern Medical Center

July 24th 2020

Safety of PD-L1 Inhibitors in mHCC

ByRichard S. Finn, MD, UCLA Health,Richard Kim, MD, Moffitt Cancer Center,Riad Salem, MD, Northwestern University Feinberg School of Medicine,Amit Singal, MD, UT Southwestern Medical Center

July 24th 2020

IMbrave150 Trial: Frontline Treatment of Advanced HCC

ByRichard S. Finn, MD, UCLA Health,Richard Kim, MD, Moffitt Cancer Center,Riad Salem, MD, Northwestern University Feinberg School of Medicine,Amit Singal, MD, UT Southwestern Medical Center

July 24th 2020

Initiation of Systemic Therapy for mHCC

ByRichard S. Finn, MD, UCLA Health,Richard Kim, MD, Moffitt Cancer Center,Riad Salem, MD, Northwestern University Feinberg School of Medicine,Amit Singal, MD, UT Southwestern Medical Center

July 24th 2020

Overview and Diagnosis of HCC

ByRichard S. Finn, MD, UCLA Health,Richard Kim, MD, Moffitt Cancer Center,Riad Salem, MD, Northwestern University Feinberg School of Medicine,Amit Singal, MD, UT Southwestern Medical Center

July 24th 2020

Latest Updated Articles

Updates in Frontline Treatment of Metastatic Liver Cancer
July 24th 2020
Initiation of Systemic Therapy for mHCC
July 24th 2020
Overview and Diagnosis of HCC
July 24th 2020
mHCC: Influence of PD-L1 Inhibitors on Second-Line Therapy
July 24th 2020
ASCO 2020 Data for Treatment of Advanced HCC
July 24th 2020
Role of VEGF TKIs for Treatment of HCC
July 24th 2020

Trending on OncLive

FDA Approves Pirtobrutinib for Previously Untreated CLL/SLL

The OncFive: Top Oncology Articles for the Week of 9/27/2026

AUA Releases Guideline Amendment for NMIBC

Daraxonrasib Approval Signals a New Era for RAS-Targeted Therapy in Pancreatic Cancer

FLORA-2 Updates at World Lung: Biomarker Analysis, Safety Follow-Up, and ctDNA Monitoring